Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Down syndrome and beta-amyloid deposition.

Elizabeth Head1, Ira T Lott

  • 1Institute for Brain Aging and Dementia, Department of Neurology, University of California, Irvine, California, USA. ehead@uci.edu

Current Opinion in Neurology
|March 17, 2004
PubMed
Summary

Recent research on Alzheimer's disease in Down syndrome reveals beta-amyloid accumulation occurs early, both intracellularly and extracellularly. Understanding these pathways is crucial for developing targeted therapies for Down syndrome and Alzheimer's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood biomarkers predict conversion from cognitively stable to mild cognitive impairment or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Low frequency blood-oxygen-level-dependent oscillations, <i>APOE4,</i> and plasma pTau<sub>217</sub>.

Journal of Alzheimer's disease : JAD·2026
Same author

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome.

Obesity (Silver Spring, Md.)·2026
Same author

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.

Acta neuropathologica·2026

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Alzheimer's disease (AD) therapeutics aim to reduce beta-amyloid.
  • These strategies are relevant for AD in Down syndrome, which shares amyloid pathology.
  • Down syndrome individuals have a genetic predisposition to early-onset Alzheimer's due to chromosome 21.

Purpose of the Study:

  • To review recent advances in beta-amyloid pathogenesis in Down syndrome.
  • To summarize novel findings on the timing and location of beta-amyloid accumulation.
  • To highlight implications for therapeutic interventions.

Main Methods:

  • Literature review of studies published within the past year.
  • Analysis of research focusing on early events in beta-amyloid accumulation.

Related Experiment Videos

  • Synthesis of findings on beta-amyloid precursor protein cleavage enzyme 2 (BACE2) and its role.

    • Main Results:

    • Research now focuses on early pathogenesis, identifying soluble and intracellular beta-amyloid accumulation preceding plaques.
    • Increased beta-amyloid levels may stem from elevated BACE2 expression on chromosome 21.
    • Beta-amyloid accumulation appears to differentially impact development and aging in Down syndrome.

    Conclusions:

    • Significant progress has been made in understanding beta-amyloid pathogenesis in Down syndrome.
    • Gaps remain in knowledge regarding beta-amyloid degradation and clearance pathways.
    • Clinical trials are needed to test therapeutic strategies, considering the unique mechanisms in Down syndrome.